Table 3.
Multivariate analysis of predictions of overall survival of men with metastatic castration-resistant prostate cancer treated with cabazitaxel
| HR | 95% CI | P value | ||
|---|---|---|---|---|
| Lower | Upper | |||
| Age (≥71.2 years vs < 71.2) | 3.4 | 1.3 | 9.1 | 0.013 |
| Number of cycles of docetaxel (≥10 cycles vs ≤9) | 0.8 | 0.3 | 2.8 | 0.781 |
| Baseline aBSI (≥1.0% vs < 1.0) | 5.8 | 1.1 | 30.3 | 0.031 |
| Baseline PSA (≥152.1 ng/mL vs < 152.1) | 0.8 | 0.2 | 2.9 | 0.769 |
| Baseline Hb (< 11.0 g/dL vs ≥11.0) | 2.6 | 1.1 | 6.2 | 0.034 |
| Baseline LDH (≥262 IU/L vs < 262) | 3.3 | 1.3 | 8.6 | 0.014 |
| Baseline ALP (≥414 IU/L vs < 414) | 0.5 | 0.2 | 1.6 | 0.255 |
aBSI automated bone scan index, ALP alkaline phosphatase, Hb hemoglobin, LDH lactate dehydrogenase, PSA prostate-specific antigen